When Dylan Jovine releases a new biotech, it pays to act fast.
Immunogen was taken over
33 days after he said it would for a 463% gain... We just sold Viking Therapeutics for a
273% gain... He sold Chemocentryx for a
300% gain... And, today I have some great news:
He just released his
#1 Biotech for March. I urge you to get the details on his latest pick before it's too late.
You'll discover:
1. How a $4 micro-cap beat the odds to win an FDA approval on a new kind of
"Smart Chemo" that's like a heat-seeking missile against cancer. 2. Why the
Journal Nature is calling it,
"The Dawn of a New Era Against Cancer." 3. Why Big Pharma giants
Pfizer, AbbVie, Merck and Johnson & Johnson put
$60 billion into this treatment within the past 12 months. Get the name of the stock here >>> Never before has so much money invested in a new cancer treatment so quickly.
Morgan Stanley estimates the market is worth at least $140 billion.
But right now, its stock price is just a tiny fraction of that size.
See why this $4 "Smart Chemo" stock can soar 300% (or more) >>> All the best,
Simmy Adelman, Publisher
Behind the Markets 
